Phaseline

Targets › IL11

IL11 (Interleukin-11): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 1, 2 Phase 2; Other, Respiratory, Oncology; next expected readout Dec 2026.

Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. Also promotes the proliferation of hepatocytes in response to liver damage. (UniProt, P20809)

Open in Phaseline: the race on IL11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mabwell (Shanghai) Bioscience9MW3811
anti-IL-11 monoclonal antibody
IL11Phase 2ScarDec 2026
Fudan UniversityrhG-CSF + rhIL-11
Recombinant granulocyte-colony stimulating factor combined with recombinant interleukin-11
CSF3, IL11Phase 2Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)Dec 2026
Shanghai Huaota BiopharmaceuticalHB0056
Bispecific antibody targeting TSLP and IL-11
TSLP, IL11Phase 1Healthy; AsthmaAug 2027

Conditions

Healthy (1) Asthma (1) Scar (1) Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) (1)

Modalities

small molecule (3)

Companies

Shanghai Huaota Biopharmaceutical (1) Mabwell (Shanghai) Bioscience (1) Fudan University (1)

Related targets

TSLP (1) CSF3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.